JPT, Institute for Medical Immunology at the Charite Partner on Dx for CFS | GenomeWeb

NEW YORK (GenomeWeb News) – JPT Peptide Technologies and The Institute for Medical Immunology at the Charite in Berlin announced on Wednesday an agreement to develop serological peptide biomarkers for the differential diagnosis of chronic fatigue syndrome.

Under the terms of the deal, JPT will combine its high-content peptide microarray technology with the institute's expertise in diagnosing patients with chronic fatigue syndrome in order to discover biomarkers that can be developed into diagnostic tools.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.